Global Allogeneic T Cell Therapies Market Report and Forecast 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Allogeneic T Cell Therapies Market Overview 
    3.1    Global Allogeneic T Cell Therapies Market Historical Value (2017-2023) 
    3.2    Global Allogeneic T Cell Therapies Market Forecast Value (2024-2032)
4    Global Allogeneic T Cell Therapies Market Landscape
    4.1    Global Allogeneic T Cell Therapies Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Allogeneic T Cell Therapies Product Landscape
        4.2.1    Analysis by Product Type
        4.2.2    Analysis by Indications
        4.2.3    Analysis by End User
5    Global Allogeneic T Cell Therapies Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Allogeneic T Cell Therapies Market Segmentation  
    6.1    Global Allogeneic T Cell Therapies Market by Product Type
        6.1.1    Market Overview
        6.1.2    Chimeric Antigen Receptor (CAR) T Cell Therapies 
        6.1.3    T Cell Receptor (TCR) Therapies 
        6.1.4    Others
    6.2    Global Allogeneic T Cell Therapies Market by Therapeutics Indications
        6.2.1    Market Overview
        6.2.2    Cancer
        6.2.3    Autoimmune Diseases
        6.2.4    Infectious Diseases 
        6.2.5    Others
    6.3    Global Allogeneic T Cell Therapies Market by End User
        6.3.1    Market Overview
        6.3.2    Hospitals
        6.3.3    Specialty Clinics
        6.3.4    Research Institutes
        6.3.5    Others
    6.4    Global Allogeneic T Cell Therapies Market by Region
        6.4.1    Market Overview
        6.4.2    North America 
        6.4.3    Europe
        6.4.4    Asia Pacific
        6.4.5    Latin America
        6.4.6    Middle East and Africa
7    North America Allogeneic T Cell Therapies Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Allogeneic T Cell Therapies Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Allogeneic T Cell Therapies Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Allogeneic T Cell Therapies Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Allogeneic T Cell Therapies Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
    16.1.1    US FDA
    16.1.2    EU EMA
    16.1.3    INDIA CDSCO
    16.1.4    JAPAN PMDA
    16.1.5    Others
17    Supplier Landscape
    17.1    Athersys Inc.
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisition
        17.1.5    Certifications
    17.2    Mesoblast Ltd.
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisition
        17.2.5    Certifications
    17.3    Biorestorative Therapies Inc.
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisition
        17.3.5    Certifications
    17.4    Pluristem Inc.
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisition
        17.4.5    Certifications
    17.5    Brainstorm Cell Limited.
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisition
        17.5.5    Certifications
    17.6    ViaCyte Inc.
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisition
        17.6.5    Certifications
    17.7    Gamida Cell
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisition
        17.7.5    Certifications
    17.8    HOPE BIOSCIENCES
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisition
        17.8.5    Certifications
    17.9    Cellular Biomedicine Group
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisition
        17.9.5    Certifications
    17.10    Smith+Nephew
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisition
        17.10.5    Certifications
    17.11    MEDIPOST
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisition
        17.11.5    Certifications
    17.12    ANTEROGEN.CO, LTD.
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisition
        17.12.5    Certifications
    17.13    NuVasive Inc.
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisition
        17.13.5    Certifications
    17.14    RTI Surgical
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisition
        17.14.5    Certifications
    17.15    AlloSource
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisition
        17.15.5    Certifications
    17.16    JCR Pharmaceuticals Co. Ltd.
        17.16.1    Financial Analysis
        17.16.2    Product Portfolio
        17.16.3    Demographic Reach and Achievements
        17.16.4    Mergers and Acquisition
        17.16.5    Certifications
    17.17    Takeda Pharmaceutical Company Limited
        17.17.1    Financial Analysis
        17.17.2    Product Portfolio
        17.17.3    Demographic Reach and Achievements
        17.17.4    Mergers and Acquisition
        17.17.5    Certifications
18    Global Allogeneic T Cell Therapies Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)
    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket

 
*Additional insights provided are customisable as per client requirements.